首页 > 最新文献

Immuno-oncology technology最新文献

英文 中文
30P The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100912
T.S. Martins , B.F.C. Correia , D.S.C.P. Grosa , R.M.S. Salvador , I. Brites , C.X. de Sousa , I.M.R. Matos Pina , S. Braga , A. Jacinto , G. Cabral
{"title":"30P The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies","authors":"T.S. Martins , B.F.C. Correia , D.S.C.P. Grosa , R.M.S. Salvador , I. Brites , C.X. de Sousa , I.M.R. Matos Pina , S. Braga , A. Jacinto , G. Cabral","doi":"10.1016/j.iotech.2024.100912","DOIUrl":"10.1016/j.iotech.2024.100912","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100912"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
66MO Durvalumab after radiotherapy (RT) in patients (pts) with unresectable stage III NSCLC ineligible for chemotherapy (CT): Final analysis of the phase II DUART study
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100809
A.R. Filippi , M. R. García Campelo , J-B. Paoli , D. Kowalski , C. Bennati , P. Borghetti , D. Cortinovis , A. Delmonte , C. Genova , R. Mroz , S. Nawrocki , I. Toledano , G. Tonini , F. Agustoni , G. Wetherill , I. Diaz Perez , N. Georgoulia , R. Dziadziuszko
{"title":"66MO Durvalumab after radiotherapy (RT) in patients (pts) with unresectable stage III NSCLC ineligible for chemotherapy (CT): Final analysis of the phase II DUART study","authors":"A.R. Filippi , M. R. García Campelo , J-B. Paoli , D. Kowalski , C. Bennati , P. Borghetti , D. Cortinovis , A. Delmonte , C. Genova , R. Mroz , S. Nawrocki , I. Toledano , G. Tonini , F. Agustoni , G. Wetherill , I. Diaz Perez , N. Georgoulia , R. Dziadziuszko","doi":"10.1016/j.iotech.2024.100809","DOIUrl":"10.1016/j.iotech.2024.100809","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100809"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143175999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
77P A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100820
M. Persano , L. Fornaro , L. Antonuzzo , T. Satake , H. Vandeputte , J. Lucchetti , J.W. Kim , O. Abidoye , I.G. Rapposelli , S. Tamberi , F. Finkelmeier , G. Giordano , F. Nicchetti , H.J. Chon , C. Yoo , S.L. Chan , M. Scartozzi , S. Lonardi , L. Rimassa , A. Casadei Gardini
{"title":"77P A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab","authors":"M. Persano , L. Fornaro , L. Antonuzzo , T. Satake , H. Vandeputte , J. Lucchetti , J.W. Kim , O. Abidoye , I.G. Rapposelli , S. Tamberi , F. Finkelmeier , G. Giordano , F. Nicchetti , H.J. Chon , C. Yoo , S.L. Chan , M. Scartozzi , S. Lonardi , L. Rimassa , A. Casadei Gardini","doi":"10.1016/j.iotech.2024.100820","DOIUrl":"10.1016/j.iotech.2024.100820","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100820"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
79P Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100822
A. Ramaswamy , V. Shenoy , A. Bahl , A. Kapoor , V. Talwar , V. Muddu , A. Rauthan , R. Pinninti , A.M. Khan , S.J. Rajappa , N. Rohatgi , M. Sharma , P.G. Bhargava , A. Gupta , B. Sansar , U. Batra , V.S. Ostwal
{"title":"79P Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis","authors":"A. Ramaswamy , V. Shenoy , A. Bahl , A. Kapoor , V. Talwar , V. Muddu , A. Rauthan , R. Pinninti , A.M. Khan , S.J. Rajappa , N. Rohatgi , M. Sharma , P.G. Bhargava , A. Gupta , B. Sansar , U. Batra , V.S. Ostwal","doi":"10.1016/j.iotech.2024.100822","DOIUrl":"10.1016/j.iotech.2024.100822","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100822"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
23P Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100905
J.M. Berger , E. Tomasich , V. Sunder-Plassmann , M. Kleinberger , P. Hettegger , L. Gottmann , I. Solano Henao , M. Korpan , U. Setinek , A. Valipour , M.J. Hochmair , L. Beer , H. Prosch , R. Kain , J. Furtner , G. Heller , M. Preusser , A.S. Berghoff
{"title":"23P Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response","authors":"J.M. Berger , E. Tomasich , V. Sunder-Plassmann , M. Kleinberger , P. Hettegger , L. Gottmann , I. Solano Henao , M. Korpan , U. Setinek , A. Valipour , M.J. Hochmair , L. Beer , H. Prosch , R. Kain , J. Furtner , G. Heller , M. Preusser , A.S. Berghoff","doi":"10.1016/j.iotech.2024.100905","DOIUrl":"10.1016/j.iotech.2024.100905","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100905"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143178089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
72P Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100815
T. Lim , K. Montazeri , A. Desilets , A.N. Shoushtari , R. Seedor , M. Orloff , T. Sato , M. Caplan , M. El-Ashmawy , B. Izar , S. Khan , R.D. Carvajal , I. Mehmi , O. Hamid , R. Sullivan
{"title":"72P Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)","authors":"T. Lim , K. Montazeri , A. Desilets , A.N. Shoushtari , R. Seedor , M. Orloff , T. Sato , M. Caplan , M. El-Ashmawy , B. Izar , S. Khan , R.D. Carvajal , I. Mehmi , O. Hamid , R. Sullivan","doi":"10.1016/j.iotech.2024.100815","DOIUrl":"10.1016/j.iotech.2024.100815","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100815"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143175923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
84P Safety of treatment with immune checkpoint inhibitors in older adults with non-small cell lung cancer
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100827
V. Dougoud-Chauvin , O. Trian , R. Rudolf , A. Curioni-Fontecedro
{"title":"84P Safety of treatment with immune checkpoint inhibitors in older adults with non-small cell lung cancer","authors":"V. Dougoud-Chauvin , O. Trian , R. Rudolf , A. Curioni-Fontecedro","doi":"10.1016/j.iotech.2024.100827","DOIUrl":"10.1016/j.iotech.2024.100827","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100827"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
28P Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100910
P. Ulivi , M. Canale , P. Cravero , M. Urbini , G. Marisi , F. Citarella , K. Andrikou , L. Crinò , A. Delmonte
{"title":"28P Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors","authors":"P. Ulivi , M. Canale , P. Cravero , M. Urbini , G. Marisi , F. Citarella , K. Andrikou , L. Crinò , A. Delmonte","doi":"10.1016/j.iotech.2024.100910","DOIUrl":"10.1016/j.iotech.2024.100910","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100910"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143139346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
73P Impact of assessment-to-treatment interval on the predictive value of PD-L1 expression in melanoma
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100816
C.D. Vestergaard , M. Donia , H. Schmidt , A.A. Luczak , L. Bastholt , E. Ellebaek , I.M. Svane
{"title":"73P Impact of assessment-to-treatment interval on the predictive value of PD-L1 expression in melanoma","authors":"C.D. Vestergaard , M. Donia , H. Schmidt , A.A. Luczak , L. Bastholt , E. Ellebaek , I.M. Svane","doi":"10.1016/j.iotech.2024.100816","DOIUrl":"10.1016/j.iotech.2024.100816","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100816"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143175924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
68P Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Immuno-oncology technology
Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100811
A. Soria Rivas , M.A. Berciano Guerrero , E. Muñoz-Couselo , P.C. Cerezuela-Fuentes , C. Aguado , P. Ayala de Miguel , G. Crespo Herrero , L. Gutierrez Sanz , L. Ostios Garcia , D. Vilanova Larena , S. Martin Algarra , I. Marquez-Rodas
{"title":"68P Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study","authors":"A. Soria Rivas , M.A. Berciano Guerrero , E. Muñoz-Couselo , P.C. Cerezuela-Fuentes , C. Aguado , P. Ayala de Miguel , G. Crespo Herrero , L. Gutierrez Sanz , L. Ostios Garcia , D. Vilanova Larena , S. Martin Algarra , I. Marquez-Rodas","doi":"10.1016/j.iotech.2024.100811","DOIUrl":"10.1016/j.iotech.2024.100811","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100811"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Immuno-oncology technology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1